Reaching Others University at Buffalo - The State University of New York
Skip to Content
Andrew                         Talal

Andrew H. Talal MD, MPH

Department of Medicine

Professor and Chief, Gastroenterology, Hepatology, and Nutrition

Specialty/Research Focus

Gastroenterology; Infectious Disease; Liver (Hepatology)

 
top-left cornertop-right corner
Professional Summary:

As chief of the Division of Gastroenterology, Hepatology and Nutrition (GI) in the Department of Medicine as well as in the Kaleida Health System, my charge is to develop and expand clinical, educational and research efforts related to liver disease. By supporting Erie County Medical Center’s liver clinic through UBMD, we have tripled the clinic’s capacity to treat patients with viral hepatitis and other forms of liver disease. We also have established comprehensive liver clinics at Buffalo General Medical Center to evaluate patients with liver disease referred from throughout Western New York. In addition, we provide clinical support to the Buffalo VA Medical Center in order to deliver uniformly excellent clinical care to patients with liver disease cared for at hospitals and clinics affiliated with UB’s medical school. We offer trial therapies to patients with viral hepatitis and other forms of liver disease if they meet the protocol criteria of our clinical trials. Our patient-care efforts include digital outreach: my faculty and I co-authored an article for the inaugural issue of the patient-oriented online magazine “HCV Next.”

My lab has received multi-year funding for its research programs in translational and clinical research. During the course of our translational research, members of my lab and I developed techniques for animal and human liver sampling that will enable sorting of liver cells in order to understand drug distribution in the liver during treatment and to develop ways to measure liver drug concentration. These translational research techniques will enable physicians to base drug dosing on the data gathered from the site of antiviral action in the liver instead of measuring the plasma concentration that is more reflective of systemic exposure. This may be an important breakthrough because of the fine line between drug efficacy and toxicity: the techniques will help physicians pinpoint the precise amount of drug needed for maximum benefit to the patient.

In the area of clinical research, we are studying care models for viral hepatitis. We are conducting a study sponsored by the Centers for Disease Control and Prevention (CDC) Foundation to assess telemedicine to treat hepatitis C (HCV) in patients who are in treatment for substance use. By creating processes that simplify testing and improve provider and patient awareness and by expanding recommendations for HCV screening, patients can receive more timely care and treatment.

I teach GI fellows, residents and students in outpatient and inpatient settings. I also teach first- and second-year medical students in small groups and research seminars with pharmacology graduate students. I am very interested in mentoring, and I supervise residents and fellows in clinical research as well as in my laboratory. The enriching experience my trainees receive affords them excellent placement opportunities once their training is complete. A number of my former trainees so valued their work with my division that they joined it as faculty members.

Education and Training:
  • Research Associate & Clinical Scholar, The Rockefeller University, Aaron Diamond AIDS Research Center (2000)
  • Fellowship, Medicine, Division of Gastroenterology, University of North Carolina (1996)
  • MPH, Epidemiology, University of North Carolina (1996)
  • Fellowship, Medicine, University of North Carolina (1995)
  • Internship, Internal Medicine, University of Iowa (1993)
  • MD, Internal Medicine, University of Texas Health Science Center (1990)
Employment:
  • Chief of Gastroenterology, Kaleida Health System (2013-present)
  • Chief of Gastroenterology, Erie County Medical Center (2012-present)
  • Professor, University at Buffalo (2012-present)
  • Adjunct Associate Professor, Columbia University College of Physician and Surgeons (2006-present)
  • Adjunct Associate Professor, New York University School of Medicine (2005-present)
  • Adjunct Clinical Attending Physician, Beth Israel Medical Center (2010–2012)
  • Associate Professor of Medicine, Weill Cornell Medical College (2005–2012)
  • Associate Attending Physician, New York Presbyterian Hospital (2005–2012)
  • Associate Attending Physician, Rockefeller University Hospital (2001–2012)
  • Assistant Professor of Medicine, Weill Cornell Medical College (2000–2005)
  • Clinical Instructor, Department of Medicine, University of North Carolina (1993–1996)
See All (11 Total) >
Awards and Honors:
  • Buffalo's Health Care 50 (2013)
  • Clinical Infectious Diseases Award (2010)
  • Clinton Global Initiatives Award, William Clinton Foundation (2006)
  • Travel Award to American Society for Clinical Investigation Annual Meeting (2005)
  • Mentored Physician-Scientist Development Award (1998)
  • Clinical Scholar Research Award (1996)
  • Young Investigators Award (1996)

Research Expertise:
  • Liver disease
Grants and Sponsored Research:
  • December 2013–November 2020
    HIV/AIDS Clinical Trials Unit
    ACTG sponsored by the National Institute of Allergy and Infectious Disease (NIAID) (University of Rochester)
    Role: Co-Investigator
    $48,496
  • February 2013–December 2015
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL 2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary t
    Gilead Sciences
    Role: Principal Investigator
  • February 2013–December 2015
    A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like 2 (LOXL 2) in Subjects with Compensated Cirrhosis Secondary to NASH.
    Gilead Sciences
    Role: Principal Investigator
  • November 2012–March 2015
    Prevention, Evaluation and Treatment of HCV in Opiate Agonist Treatment Settings (PET-C)
    CDC Foundation/VHAC
    Role: Principal Investigator
    $130,000
  • November 2011–December 2014
    Phase 2a, Pilot, Open Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-like Molecule 2 (LOXL2) in Subjects with Fibrosis of the Liver.
    Gilead Sciences
    Role: Principal Investigator
  • January 2010–January 2012
    Assessment by Meta-analysis of Treatment of Addiction as a Determinant of Successful Treatment Response for Hepatitis C Virus Infection in Drug Users
    Merck and Company
    Role: Co-Investigator
  • January 2010–January 2012
    Risks Factors for AID among IV Drug users(1R21DA030272-01)
    NIH/NIDA (Levy)
    Role: Co-Investigator
  • January 2006–January 2012
    Adult AIDS Clin Trials Program-Cornell Clinical Trials Unit(U01-AI-69419)
    NIH/NIAID (Gulick)
    Role: Co-Investigator
  • January 2004–January 2009
    Acute HCV Infection in Injection Drug Users
    NIH/R01
    Role: Co-Investigator
See All (9 Total) >

Evaluative Studies and Case Reports:
Journal Articles:
See All (77 Total) >

Professional Memberships:
  • American Association of Immunologists (2004–2010)
  • American Association for the Study of Liver Diseases (2004)
  • American College of Physicians (Fellow, American College of Physicians) (2004)
  • American Association for the Advancement of Science (2001–2010)
  • American College of Physicians (Third Place, ACP Clinical Vignette Competition) (1993)
  • American College of Gastroenterology (1993)
  • American College of Physicians (1992–2004)
  • American Gastroenterological Association (1992)
Presentations:
  • "Intrahepatic Sampling to Understand Viral and Drug Kinetics using Fine Needle Aspiration" HEP DART 2013: Frontiers in Drug Development for Viral Hepatitis (2013)
  • "Hepatitis C in 2013: Where Are We, Who Should We Treat and With What Should We Treat" ASAM Annual Medical-Scientific Conference, Chicago, IL, American Society of Addiction Medicine, Session on Hepatitis C in 2013 (2013)
  • "Hepatitis C Treatment in Drug Users: Is It Finally Appearing on the Radar?" Yale Liver Center Research Seminar, New Haven, CT, Yale University Medical Center (2013)
  • "How to Approach the Paradigm in the Addiction Population" The New Paradigm of HCV Therapy - Integration of Oral Therapies into Best Practices, Boston, MA, Harvard Medical School, Liver Institute and Foundation for Education and Research (2013)
  • "Addressing HCV Clinical Gaps Among Special Patient Populations" HIV Grand Rounds, VA Western NY, Buffalo, NY, VA Western New York (2011)
  • "Addressing HCV Clinical Gaps Among Special Patient Populations" HIV Grand Rounds, Roosevelt Hospital Center, New York, NY, Roosevelt Hospital Center, New York, NY (2011)
  • "Clinical management of HCV in patients with and without HIV" Physicians Research Network, New York University (2011)
  • "HCV Management in Patients on Opiate Agonist Therapy via Telemedicine: A Non-comparative, Feasibility Study." Abbott Molecular Diagnostics Grand Rounds, Des Plaines IL (2011)
  • "Lessons Learned from Liver Fibrosis Trials" Gilead Sciences Fibrosis Advisory Board, South Francisco, CA (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C" Addiction Research and Treatment Corporation, Brooklyn, NY (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C" Infectious Disease Update 2011, New York, NY, Weill Cornell Medical College (2011)
  • "New Developments in the Treatment of Chronic Hepatitis C." New York/New JerseyAIDS Education and Training Center Faculty Development (2011)
  • "Prevention, Evaluation and Treatment for HCV Management" Opicare Advisory Board Meeting, Brussels, Belgium (2011)
  • "Prevention, Evaluation and Treatment of Hepatitis C in Opiate Agonist Treatment Settings: PET-C HCV Management" Steering Committee Meeting, Viral Hepatitis Action Coalition: Models of Prevention, Treatment and Care (2011)
  • "Treating HCV/HIV Coinfection: Outcomes and Impact on Disease Status" NY Methodist Hospital (2011)
  • "Treatment of Chronic Hepatitis C in HIV infection, New Advances in Hep C Therapy: The World is Changing" NATAP Forum, New York University School of Medicine, New York, NY (2011)
  • "Can we ever get to a world without interferon?" Hepatitis C Global Therapeutic Expert Forum, Dallas, TX (2010)
  • "Chemokines – A View into Virus-Host Interactions" Mt Sinai School of Medicine, New York, NY (2010)
  • "Clinical Applications in HCV: Steve, 36-Year-Old with Previous Injection Drug Use (IDU)" Orange CA, Anaheim CA, and San Diego, CA (2010)
  • "New Horizons in the Treatment of Hepatitis C" New York/New Jersey AIDS Education and Training Center Faculty Development, New Platz, NY (2010)
  • "New Horizons in the Treatment of Hepatitis C." Addiction Research and Treatment Corporation, Brooklyn, NY (2010)
  • "Patient-centered approaches to Hepatitis C management" Molecular Center of Excellence Alliance, Philadelphia, PA (2010)
  • "Treatment of the IVDU Patient Population: Outcomes from a Multidisciplinary Approach to Treatment, Genentech, South San Francisco, CA" Genentech (2010)
  • "Treatment of the IVDU Patient Population: Outcomes from Multidisciplinary Approach to Treatment" Opicare Advisory Board Meeting, Zurich, Switzerland (2010)
  • "Chemokines – A View into Virus-Host Interactions" XVI Annual Viral Hepatitis B and C Meeting, Athens, Greece, XVI Annual Viral Hepatitis B and C Meeting, Athens, Greece (2009)
  • "Predictive Factors of Response to the Treatment of HCV" Brookdale Hospital Center, Brooklyn, NY (2009)
  • "Predictive Factors of Response to the Treatment of HCV" Wykoff Hospital Center, Brooklyn, NY, Wykoff Hospital Center, Brooklyn, NY (2009)
See All (27 Total) >
Service Activities:
  • Aids Clinical Trials Group (ACTG) Hepatitis Transformative Science Group; ACTG HEP TSG; Member (2014–2015)
  • American Association for the Study of Liver Diseases; Abstract Reviewer, Digestive Disease Week 2014; Ad Hoc Reviewer (2014)
  • Co-moderator, Early Morning Workshop (EMW-2) HCV Replication, The Liver Meeting 2013, Washington, DC; Co-moderator, Early Morning Workshop (EMW-2) HCV Replication, The Liver Meeting 2013, Washington, DC; Moderator (2013)
  • Addiction Research and Treatment Corporation (ARTC); Advisory Board (2013)
  • Journal of Hepatology; Editorial Board Member (2010)
  • Hepatic Medicine: Evidence and Research; (Honorary); Editorial Board Member (2008)
  • Translational Research; Editorial Board Member (2006)
  • Empire Clinical Research Investigator Program Review Panel, New York Presbyterian Hospital; Member (2003–2004)
  • New York Presbyterian Hosp-Weill-Cornell Medical College Children’s Clinical Research Center; Reviewer (2003)
  • AIDS; Ad Hoc Reviewer (1998)
  • AIDS Patient Care STDS; Ad Hoc Reviewer (1998)
  • Alimentary Pharmacology and Therapeutics; Ad Hoc Reviewer (1998)
  • American Journal of Gastroenterology; Ad Hoc Reviewer (1998)
  • American Journal of Pathology; Ad Hoc Reviewer (1998)
  • Annals of Internal Medicine; Ad Hoc Reviewer (1998)
  • Clinical Infectious Diseases; Ad Hoc Reviewer (1998)
  • Gastroenterology; Ad Hoc Reviewer (1998)
  • Hepatology; Ad Hoc Reviewer (1998)
  • HIV Clinical Trials; Ad Hoc Reviewer (1998)
  • Journal of Interferon and Cytokine Research; Ad Hoc Reviewer (1998)
  • Journal of Viral Hepatitis; Ad Hoc Reviewer (1998)
  • Journal of Acquired Immunodeficiency Syndromes; Ad Hoc Reviewer (1998)
  • Journal of Autoimmunity; Ad Hoc Reviewer (1998)
  • Journal of Clinical Gastroenterology; Ad Hoc Reviewer (1998)
  • Journal of European Medical Students` Association; Ad Hoc Reviewer (1998)
  • Journal of Experimental Medicine; Ad Hoc Reviewer (1998)
  • Journal of General Internal Medicine; Ad Hoc Reviewer (1998)
  • Journal of Hepatology; Ad Hoc Reviewer (1998)
  • Journal of Infectious Diseases; Ad Hoc Reviewer (1998)
  • Journal of Medical Virology; Ad Hoc Reviewer (1998)
  • Journal of Substance Abuse Treatment; Ad Hoc Reviewer (1998)
  • Journal of Urban Health; Ad Hoc Reviewer (1998)
  • Liver International; Ad Hoc Reviewer (1998)
  • Nature Biotechnology; Ad Hoc Reviewer (1998)
  • PloS ONE; Ad Hoc Reviewer (1998)
  • Science Translational Medicine; Ad Hoc Reviewer (1998)
  • The AIDS Reader; Ad Hoc Reviewer (1998)
  • Translational Research; Ad Hoc Reviewer (1998)
  • Transplantation; Ad Hoc Reviewer (1998)
  • Virology; Ad Hoc Reviewer (1998)

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

Clinical and Translational Research Center
875 Ellicott Street
Suite 6089
Buffalo, NY 14203
Phone: 716-888-4738
Fax: 716-854-1397
Email: ahtalal@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile